Published in Expert Rev Neurother on June 01, 2010
Pain management strategies for neuropathic pain in Fabry disease - a systematic review. BMC Neurol (2016) 1.37
Italian guidelines for primary headaches: 2012 revised version. J Headache Pain (2012) 1.10
Optogenetic delay of status epilepticus onset in an in vivo rodent epilepsy model. PLoS One (2013) 0.99
Bicuspid aortic valve and severe aortic stenosis in a newborn exposed to carbamazapine during pregnancy. J Turk Ger Gynecol Assoc (2014) 0.94
Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A (2012) 0.92
Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research. Epilepsy Behav (2013) 0.90
Medical and psychological risks and consequences of long-term opioid therapy in women. Pain Med (2012) 0.88
Developmental effects of antiepileptic drugs and the need for improved regulations. Neurology (2015) 0.86
Teratogenic potential of antiepileptic drugs in the zebrafish model. Biomed Res Int (2013) 0.79
Brief report novel mechanism for valproate-induced teratogenicity. Birth Defects Res A Clin Mol Teratol (2014) 0.76
Facial Dysmorphism: An Unreported Teratogenicity with Levetiracetam. J Clin Diagn Res (2017) 0.75
Neurological teratogenic effects of antiepileptic drugs during pregnancy. Exp Ther Med (2016) 0.75
Review about gabapentin misuse, interactions, contraindications and side effects. J Exp Pharmacol (2017) 0.75
Prospective, case-control study on the effect of pregnancy on seizure frequency in women with epilepsy. Neurol Sci (2014) 0.75
The incidence of congenital heart disease. J Am Coll Cardiol (2002) 16.13
Severe persistent visual field constriction associated with vigabatrin. BMJ (1997) 12.81
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem (2001) 6.85
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med (2009) 6.66
Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med (2000) 5.37
Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry (2005) 4.86
Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep (1992) 4.22
In utero antiepileptic drug exposure: fetal death and malformations. Neurology (2006) 3.64
Arene oxides: a new aspect of drug metabolism. Science (1974) 3.34
The teratogenicity of anticonvulsant drugs. N Engl J Med (2001) 3.09
Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med (1991) 2.96
Lamotrigine and the risk of malformations in pregnancy. Neurology (2005) 2.91
Major malformations in offspring of women with epilepsy. Neurology (2003) 2.64
Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr (2004) 2.34
Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology (2008) 2.04
Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res (2008) 2.02
Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology (2008) 1.96
Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology (2005) 1.93
Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia (1986) 1.82
The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol (2004) 1.82
The fetal hydantoin syndrome. J Pediatr (1975) 1.80
Phenobarbital induction of cytochrome P-450 gene expression. Biochem J (1992) 1.77
Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology (2005) 1.74
Folate and neural tube defects. Am J Clin Nutr (2007) 1.73
Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol (1999) 1.73
Congenital malformations due to antiepileptic drugs. Epilepsy Res (1999) 1.71
Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol (2009) 1.70
Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry (2008) 1.67
Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet (1975) 1.51
Maternal valproate dosage and foetal malformations. Acta Neurol Scand (2005) 1.51
Ceft palate in the offspring of female mice treated with phenytoin. Lancet (1969) 1.36
Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol (2006) 1.33
Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J (2005) 1.31
The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol (2002) 1.27
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia (2007) 1.19
Periconceptional folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod Biol (1998) 1.16
Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia (1984) 1.16
Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav (2008) 1.14
Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology (2008) 1.14
Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology (2006) 1.13
Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf (2007) 1.13
The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol (2008) 1.12
Phenytoin teratogenesis: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J Pharmacol Exp Ther (1977) 1.10
Genetic predisposition to phenytoin-induced birth defects. Lancet (1985) 1.09
Comparative study of the teratogenicity of phenobarbitone, diphenylhydantoin and carbamazepine in mice. Toxicology (1977) 1.04
Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin--developmental effects of valproic acid. Crit Rev Toxicol (2006) 1.04
A new metabolite of 5,5-diphenylhydantoin (Dilantin). Biochem Biophys Res Commun (1970) 1.01
Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med (1983) 1.00
Teratogen update: fetal hydantoin effects. Teratology (1986) 1.00
Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. J Neurol (2008) 0.99
Antiepileptic drug use in women of childbearing age. Epilepsy Behav (2009) 0.99
Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav (2003) 0.98
Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol (2006) 0.98
Impaired methionine synthesis and hypomethylation in rats exposed to valproate during gestation. Neurology (1999) 0.97
Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res B Dev Reprod Toxicol (2005) 0.96
Phenytoin teratogenicity in man. Lancet (1973) 0.95
Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam Appl Toxicol (1986) 0.94
Teratogenic effects of antiepileptic medications. Neurol Clin (2009) 0.92
Cardiac malformations are increased in infants of mothers with epilepsy. Pediatr Cardiol (2008) 0.91
Determination of human teratogenicity by the astute clinician method: review of illustrative agents and a proposal of guidelines. Birth Defects Res A Clin Mol Teratol (2009) 0.91
A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav (2009) 0.90
Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia (1996) 0.90
Studies on 5,5-diphenylhydantoin irreversible binding to rat liver microsomal proteins. Biochem Pharmacol (1982) 0.90
Strain differences in heat-induced neural tube defects in mice. Teratology (1986) 0.89
Congenital structural anomalies in offspring of women with epilepsy--a population-based cohort study in Finland. Int J Epidemiol (2005) 0.89
Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology (1992) 0.89
Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin (2005) 0.88
Teratogenic effects of diphenylhydantoin sodium. J Oral Ther Pharmacol (1966) 0.88
Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. Eur J Epidemiol (1992) 0.88
Guidelines for the care of women with epilepsy. Neurology (1998) 0.88
Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology (1988) 0.87
Gabapentin. Epilepsia (1995) 0.87
Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. Teratology (1988) 0.87
The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol (2007) 0.86
Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero. Curr Opin Neurol (2009) 0.86
Relation of dosage and time of administration of diphenylhydantoin to its teratogenic effect in mice. Teratology (1969) 0.86
Oxcarbazepine. Epilepsia (1999) 0.85
Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Dev Med Child Neurol (2007) 0.85
Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog Carcinog Mutagen (1996) 0.85
In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase. Mol Pharmacol (1989) 0.85
Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case-control study. BJOG (2007) 0.85
Fetal anticonvulsant syndrome in rats: dose- and period-response relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring. J Pharmacol Exp Ther (1983) 0.84
Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study. Morphologie (2004) 0.83
Valproic acid-induced spina bifida: a mouse model. Teratology (1992) 0.83
Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology (2009) 0.83
A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and primidone in mice. Toxicol Appl Pharmacol (1977) 0.83
Teratogenesis of calcium valproate in rabbits. Teratology (1986) 0.82
Strain differences in phenobarbital-induced teratogenesis in mice. Teratology (1987) 0.82
Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation. Epilepsia (2003) 0.82
Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology (2003) 0.82
Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats. Epilepsy Res (2007) 0.82
Teratogenic effects of vigabatrin in TO mouse fetuses. Teratology (1997) 0.82
The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm Genome (2012) 2.65
Neural tube defects and folate: case far from closed. Nat Rev Neurosci (2006) 2.30
A new partner for the international knockout mouse consortium. Cell (2007) 2.23
Large-scale gene trapping in C57BL/6N mouse embryonic stem cells. Genome Res (2008) 2.08
Maternal periconceptional vitamins: interactions with selected factors and congenital anomalies? Epidemiology (2002) 1.93
The planar cell polarity effector Fuz is essential for targeted membrane trafficking, ciliogenesis and mouse embryonic development. Nat Cell Biol (2009) 1.90
The continuing challenge of understanding, preventing, and treating neural tube defects. Science (2013) 1.86
Variation in IRF6 contributes to nonsyndromic cleft lip and palate. Am J Med Genet A (2005) 1.82
118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects. BMC Med Genet (2009) 1.74
Maternal smoking and the risk of orofacial clefts: Susceptibility with NAT1 and NAT2 polymorphisms. Epidemiology (2004) 1.63
A mouse model of hereditary folate malabsorption: deletion of the PCFT gene leads to systemic folate deficiency. Blood (2011) 1.62
Mid-pregnancy cotinine and risks of orofacial clefts and neural tube defects. J Pediatr (2008) 1.52
Association of selected persistent organic pollutants in the placenta with the risk of neural tube defects. Proc Natl Acad Sci U S A (2011) 1.38
Novel mutations in VANGL1 in neural tube defects. Hum Mutat (2009) 1.37
Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab (2003) 1.25
Integration of DNA sample collection into a multi-site birth defects case-control study. Teratology (2002) 1.22
Risks of human conotruncal heart defects associated with 32 single nucleotide polymorphisms of selected cardiovascular disease-related genes. Am J Med Genet A (2005) 1.18
Choline and risk of neural tube defects in a folate-fortified population. Epidemiology (2009) 1.18
Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet (2002) 1.17
Folic acid in early pregnancy: a public health success story. FASEB J (2010) 1.16
Maternal occupational exposure to polycyclic aromatic hydrocarbons: effects on gastroschisis among offspring in the National Birth Defects Prevention Study. Environ Health Perspect (2012) 1.16
Folate regulation of axonal regeneration in the rodent central nervous system through DNA methylation. J Clin Invest (2010) 1.14
Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N-transferase 1 (NAT1), and risk for orofacial clefts. Birth Defects Res A Clin Mol Teratol (2004) 1.13
Embryonic development of folate binding protein-1 (Folbp1) knockout mice: Effects of the chemical form, dose, and timing of maternal folate supplementation. Dev Dyn (2004) 1.10
Reduced folate carrier polymorphism (80A-->G) and neural tube defects. Eur J Hum Genet (2003) 1.08
Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. FASEB J (2009) 1.07
Folate pathway and nonsyndromic cleft lip and palate. Birth Defects Res A Clin Mol Teratol (2010) 1.06
Spontaneous neural tube defects in splotch mice supplemented with selected micronutrients. Toxicol Appl Pharmacol (2005) 1.06
Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population. J Hum Genet (2002) 1.06
Investigations into the etiology of neural tube defects. Birth Defects Res C Embryo Today (2004) 1.05
Whole genome microarray analysis, from neonatal blood cards. BMC Genet (2009) 1.05
Are the betaine-homocysteine methyltransferase (BHMT and BHMT2) genes risk factors for spina bifida and orofacial clefts? Am J Med Genet A (2005) 1.04
HuR/methyl-HuR and AUF1 regulate the MAT expressed during liver proliferation, differentiation, and carcinogenesis. Gastroenterology (2010) 1.04
Endothelial nitric oxide synthase (NOS3) genetic variants, maternal smoking, vitamin use, and risk of human orofacial clefts. Am J Epidemiol (2005) 1.04
Epidemiologic characteristics of anophthalmia and bilateral microphthalmia among 2.5 million births in California, 1989-1997. Am J Med Genet A (2005) 1.04
Autoantibodies to folate receptor during pregnancy and neural tube defect risk. J Reprod Immunol (2008) 1.03
Fuz controls the morphogenesis and differentiation of hair follicles through the formation of primary cilia. J Invest Dermatol (2010) 1.01
Neural and orofacial defects in Folp1 knockout mice [corrected]. Birth Defects Res A Clin Mol Teratol (2003) 1.00
Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Res (2005) 1.00
Fuz mutant mice reveal shared mechanisms between ciliopathies and FGF-related syndromes. Dev Cell (2013) 0.99
Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial defects and congenital heart defects in China. Ann Epidemiol (2005) 0.99
Associations between polymorphisms within the thymidylate synthase gene and spina bifida. Birth Defects Res A Clin Mol Teratol (2003) 0.99
Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial and conotruncal heart defects. Am J Epidemiol (2003) 0.98
Effects of dietary folate intake and folate binding protein-1 (Folbp1) on urinary speciation of sodium arsenate in mice. Toxicol Lett (2003) 0.98
Maternal smoking, genetic variation of glutathione s-transferases, and risk for orofacial clefts. Epidemiology (2005) 0.98
Mutations in planar cell polarity gene SCRIB are associated with spina bifida. PLoS One (2013) 0.98
Embryonic development in the reduced folate carrier knockout mouse is modulated by maternal folate supplementation. Birth Defects Res A Clin Mol Teratol (2008) 0.98
Reproductive consequences of oral arsenate exposure during pregnancy in a mouse model. Birth Defects Res B Dev Reprod Toxicol (2008) 0.97
Defective sumoylation pathway directs congenital heart disease. Birth Defects Res A Clin Mol Teratol (2011) 0.97
Renal tubular reabsorption of folate mediated by folate binding protein 1. J Am Soc Nephrol (2005) 0.96
Maternal and infant gene-folate interactions and the risk of neural tube defects. Am J Med Genet A (2012) 0.95
Differentially expressed genes in embryonic cardiac tissues of mice lacking Folr1 gene activity. BMC Dev Biol (2007) 0.94
Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatology (2013) 0.94
Importance of folate-homocysteine homeostasis during early embryonic development. Clin Chem Lab Med (2007) 0.93
Fetal and maternal MTHFR C677T genotype, maternal folate intake and the risk of nonsyndromic oral clefts. Am J Med Genet A (2007) 0.93
Maternal occupational chemical exposures and biotransformation genotypes as risk factors for selected congenital anomalies. Am J Epidemiol (2003) 0.93
Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A (2012) 0.92
Mouse Fkbp8 activity is required to inhibit cell death and establish dorso-ventral patterning in the posterior neural tube. Hum Mol Genet (2007) 0.91
Developmental consequences of abnormal folate transport during murine heart morphogenesis. Birth Defects Res A Clin Mol Teratol (2004) 0.91
Diabetes and obesity-related genes and the risk of neural tube defects in the national birth defects prevention study. Am J Epidemiol (2012) 0.90
Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. J Med Chem (2009) 0.90
Fuz regulates craniofacial development through tissue specific responses to signaling factors. PLoS One (2011) 0.90
Genetic basis of susceptibility to teratogen induced birth defects. Am J Med Genet C Semin Med Genet (2011) 0.89
Arsenate-induced maternal glucose intolerance and neural tube defects in a mouse model. Toxicol Appl Pharmacol (2009) 0.89
Developmental consequences of in utero sodium arsenate exposure in mice with folate transport deficiencies. Toxicol Appl Pharmacol (2005) 0.88
Autoantibodies to folate receptor alpha during early pregnancy and risk of oral clefts in Denmark. Pediatr Res (2010) 0.88
Screening for novel PAX3 polymorphisms and risks of spina bifida. Birth Defects Res A Clin Mol Teratol (2007) 0.88
Phosphatidylethanolamine N-methyltransferase (PEMT) gene polymorphisms and risk of spina bifida. Am J Med Genet A (2006) 0.87
Cardiovascular abnormalities in Folr1 knockout mice and folate rescue. Birth Defects Res A Clin Mol Teratol (2007) 0.87
Promoter haplotype combinations for the human PDGFRA gene are associated with risk of neural tube defects. Mol Genet Metab (2004) 0.87
Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia (2013) 0.86
Effects of dietary folate intake and folate binding protein-2 (Folbp2) on urinary speciation of sodium arsenate in mice. Environ Toxicol Pharmacol (2005) 0.86
Transcriptional regulation of the novel Toll-like receptor Tlr13. J Biol Chem (2009) 0.86
Variable contribution of the MTHFR C677T polymorphism to non-syndromic cleft lip and palate risk in China. Am J Med Genet A (2006) 0.85
Valproic acid-induced skeletal malformations: associated gene expression cascades. Pharmacogenet Genomics (2005) 0.85
CHKA and PCYT1A gene polymorphisms, choline intake and spina bifida risk in a California population. BMC Med (2006) 0.85
Effects of folate supplementation on the risk of spontaneous and induced neural tube defects in Splotch mice. Teratology (2002) 0.85
Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. J Reprod Immunol (2013) 0.84
Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology (2010) 0.84
A cannabinoid analogue of Delta9-tetrahydrocannabinol disrupts neural development in chick. Birth Defects Res B Dev Reprod Toxicol (2008) 0.84
Folate-regulated changes in gene expression in the anterior neural tube of folate binding protein-1 (Folbp1)-deficient murine embryos. Neurochem Res (2004) 0.84
Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice. Birth Defects Res A Clin Mol Teratol (2003) 0.84
Genetic and nutritional deficiencies in folate metabolism influence tumorigenicity in Apcmin/+ mice. J Nutr Biochem (2006) 0.84
Arsenic-induced gene expression changes in the neural tube of folate transport defective mouse embryos. Neurotoxicology (2006) 0.84
Planar cell polarity pathway genes and risk for spina bifida. Am J Med Genet A (2010) 0.83
Microarray analysis of E9.5 reduced folate carrier (RFC1; Slc19a1) knockout embryos reveals altered expression of genes in the cubilin-megalin multiligand endocytic receptor complex. BMC Genomics (2008) 0.83
Rare LRP6 variants identified in spina bifida patients. Hum Mutat (2015) 0.83
Maternal smoking during early pregnancy, GSTP1 and EPHX1 variants, and risk of isolated orofacial clefts. Cleft Palate Craniofac J (2007) 0.83
Risks of human limb deficiency anomalies associated with 29 SNPs of genes involved in homocysteine metabolism, coagulation, cell-cell interactions, inflammatory response, and blood pressure regulation. Am J Med Genet A (2006) 0.83